ClinConnect ClinConnect Logo
Search / Trial NCT06204393

To Investigate the Effect of 2019 Novel Coronavirus Infection on the Condition of Patients With Hyperthyroidism

Launched by QILU HOSPITAL OF SHANDONG UNIVERSITY · Jan 10, 2024

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how COVID-19 affects patients who have hyperthyroidism, specifically those with a condition called Graves disease. The researchers want to understand how COVID-19 might change the symptoms of hyperthyroidism and how it impacts the mental health of these patients, looking at levels of anxiety and depression before and after they contract the virus. They will also explore whether providing psychological support can help improve their well-being after dealing with COVID-19.

To be eligible for the trial, participants must be diagnosed with hyperthyroidism and have also tested positive for COVID-19. The study is open to all adults aged 18 and older. If you join, you will have regular check-ups over a year where your thyroid function and other health indicators will be monitored. This study aims to help doctors better understand the relationship between these two conditions and improve care for patients facing both hyperthyroidism and COVID-19.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. According to the diagnostic criteria of hyperthyroidism in the Chinese Guidelines for the Diagnosis and Treatment of Thyroid Diseases formulated by the Chinese Society of Endocrinology of the Chinese Medical Association, the patient had been diagnosed with hyperthyroidism.
  • 2. In accordance with the diagnostic criteria of "The diagnosis and Treatment Protocol for novel coronavirus Infection (Trial version 10).
  • Exclusion Criteria:
  • 1. Cases with incomplete data
  • 2. Patients with severe autoimmune diseases, hematological diseases and malignant tumors
  • 3. Immunodeficiency (e.g.AIDS, long-term use of corticosteroids or other immunosuppressive drugs leading to immunodeficiency)
  • 4. Follow-up was less than 30 days
  • 5. The results of thyroid function were less than 3 times

About Qilu Hospital Of Shandong University

Qilu Hospital of Shandong University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient-centered care. Affiliated with Shandong University, the hospital integrates clinical practice with education and research, fostering an environment that promotes scientific discovery and the development of new therapies. With a commitment to high standards of clinical excellence and ethical research practices, Qilu Hospital plays a pivotal role in enhancing patient outcomes and contributing to the global medical community through a diverse range of clinical trials and studies.

Locations

Jinan, Shandong, China

Patients applied

0 patients applied

Trial Officials

Kuanxiao Tang, M.D.

Principal Investigator

Qilu Hospital of Shandong University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported